SNORD58B: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD58B

NCBI ID: G26790

SNORD58B

Other Name(s): small nucleolar RNA, C/D box 58B | Small nucleolar RNA, C/D box 58B | RNA, U58B small nuclear | RNU58B | U58b

SNORD58B: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNA molecules, which play a critical role in regulating gene expression in eukaryotic cells. One of the well-known snRNAs is SNORD58B, which is a 22-kDa RNA molecule. It is located in the 58th position in the human nuclear ribonucleoprotein (RNA) sequence. SNORD58B is composed of a highly conserved C/D box region and a unique N-terminus region that contains a single base, GCA.

Expression and Functions of SNORD58B

SNORD58B is a highly expressed gene in the human body, with the highest expression levels in the brain. It is found in various cell types, including the brain, heart, and testes. SNORD58B is involved in various cellular processes, including cell growth, differentiation , and RNA metabolism.

One of the well-known functions of SNORD58B is its role in regulating gene expression. It has been shown to interact with various proteins, including histone H3A, histoneH1A and RNA-binding protein (RBP). SNORD58B controls genes by binding to these proteins. expression and plays a key role in RNA metabolism.

Another function of SNORD58B is its role in DNA damage repair. SNORD58B has been shown to play a critical role in the repair of DNA damage caused by various stress factors, such as ionizing radiation and mutagenes. It has been shown to interact with DNA repair machinery components, including the protein responsible for homologous recombination (HR) and the protein responsible for non-homologous end joining (NHEJ).

SNORD58B as a Drug Target

SNORD58B is a potential drug target due to its unique functions and the potential impact on various diseases. One of the potential strategies to target SNORD58B is to inhibit its expression. This can be achieved by small interfering RNA (siRNA) or CRISPR/Cas9 genome editing.

siRNA technology is an effective method to inhibit SNORD58B expression. By designing an siRNA targeting SNORD58B, the concentration of SNORD58B can be effectively reduced, thereby inhibiting its function on cells. Currently, a variety of siRNA molecules have been designed and used to inhibit the expression of SNORD58B. These siRNA molecules can accumulate in cells and inhibit the function of SNORD58B.

CRISPR/Cas9 genome editing is another potential strategy to target SNORD58B. This technique allows researchers to make targeted edits to the genome, including SNORD58B. By using CRISPR/Cas9 to edit the SNORD58B gene, researchers can delete or add SNORD58B to the genome, which can lead to a decrease or increase in SNORD58B expression.

Conclusion

SNORD58B is a unique small nucleolar RNA molecule that plays a critical role in regulating gene expression and DNA damage repair. It is a potential drug target due to its unique functions and the potential impact on various diseases. By inhibiting SNORD58B expression or using CRISPR/Cas9 genome editing to edit SNORD58B, researchers can potentially develop new treatments for various diseases.

Protein Name: Small Nucleolar RNA, C/D Box 58B

The "SNORD58B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD58B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets